Zoom in: The programme, called AI4CancerCure.NRW, launched Sept. 4 by state premier Hendrik Wüst and science minister Ina Brandes, aims to use artificial intelligence across cancer research and care, from cancer biology and data-driven drug design to imaging, prevention, early detection and personalised treatment.
Why it matters: NRW is trying to turn the geographical concentration of its university medicine into a shared research platform and doing so with a budget rarely seen for a single research theme at state level. A common digital infrastructure is planned to let researchers use data and algorithms across the participating sites.
The context: The scale of the investment becomes clearer compared with other recent German state investments.
- Baden-Württemberg provided about €84 million in 2023 for the construction and initial equipment of the NCT SüdWest sites in Tübingen and Ulm, part of the expansion of Germany’s National Center for Tumor Diseases.
- Schleswig-Holstein, meanwhile, is investing about €150 million in two new research centres at Kiel University to strengthen biomedical and clinical research.
- NRW itself is spending heavily on research infrastructure. From a €2.3 billion programme for universities, research, teaching and technology transfer, up to €180 million is earmarked for a new AI centre at RWTH Aachen and another €113 million for modernising physics facilities at the University of Bonn.
Yes, but: AI4CancerCure is not a single building. It is a network encompassing several university hospitals and a technical university, all focused on a clearly defined field.
What we’re watching: For biotech and pharma, perhaps the most interesting part is the programme’s proximity to drug development.
- In Bonn, €25 million is available to combine AI-driven drug design with experimental research. Plans include new AI models and GPU infrastructure, as well as automated systems for producing and testing antibodies, miniproteins, peptides and small molecules.
- Essen’s university medicine will receive €32.5 million, while Münster is getting €25 million to establish its new PRECISION.AI Oncology Centre. The Münster centre will bring together medicine, computer science, mathematics and data science, with a particular focus on using clinical, imaging and molecular data for precision oncology.
The big picture: That could make AI4CancerCure more relevant to biotech than a conventional academic research programme. NRW explicitly wants research to move into products, spinouts and collaborations with the healthcare industry. The seven university hospitals already cover much of the state’s oncology expertise, while TU Dortmund adds AI and data science capabilities. The programme can also build on existing research and data-integration infrastructure.
A different model from Mainz: A seemingly obvious comparison is the state of Rheinland-Pfalz, which in 2022 also spoke of €200 million for the Mainz-based TRON research institute. But the funding mechanism was different. According to the state government, TRON had itself generated more than €200 million through contract research and licence income, which was to be reinvested in research and infrastructure. The state’s original funding for TRON was about €13 million.
- The case nevertheless shows the leverage that relatively modest public seed funding can create when academic research, spinouts and commercialisation reinforce each other. NRW is now taking a different route: investing heavily in a statewide research infrastructure from the outset.
Lessons from Bavaria: Bavaria has pursued a similar networking idea with the Bavarian Cancer Research Center, or BZKF, founded in 2019 to connect six university hospitals in Augsburg, Erlangen, Munich, Regensburg and Würzburg.
- Pilot projects such as DigiMed and DigiOnco have highlighted the potential of combining clinical patient data with omics diagnostics and AI analysis. They have also exposed one of the central obstacles: sharing health data across institutions and navigating state, federal and European data-protection rules.
- Funding has been another constraint. Bavaria provided €7.2 million for the BZKF in 2020, rising to €10.8 million in 2022 and €15 million in 2024. The original concept had estimated that full operation would eventually require €45 million to €60 million annually.
Bottom line: NRW is starting on a much larger financial footing. If the network succeeds in making clinical data usable across institutions and links that infrastructure to experimental drug discovery, AI4CancerCure could become more than another temporary funding programme. It could provide a publicly financed platform from which new targets, drug candidates, diagnostics and AI models emerge, alongside new biotech spinouts and industry partnerships.
Sign up for our newsletter!
